Crossmark

Provocation of attacks to discover migraine signaling mechanisms and new drug targets: early history and future perspectives - a narrative review

Published Online: 2024-06-20

Authors

Olesen, Jes
Funding

Funding for this research was provided by:

Copenhagen University
License Information

Text and Data Mining valid from 2024-06-20

Version of Record valid from 2024-06-20
More Information

Article History

Received: 8 May 2024

Accepted: 21 May 2024

First Online: 20 June 2024

Declarations

:

: Jes Olesen owns stock in Novo Nordisk, Moberg Pharma and Cephagenix.

Document is current